The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...

you can see all the individual transactions, including the share price, individual, and the date! NasdaqGS:REGN Insider Trading Volume February 9th 2025 I will like Regeneron Pharmaceuticals ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results , with sales up 10.3% year on year to $3.79 billion. Its ...

Regeneron Pharmaceuticals announced positive ... As previously presented , 88% of all EYLEA HD patients maintained ≥3-month dosing intervals at the end of two years. Patients could then ...

“All of this health information—their health records and the biospecimens—are coming to us de-identified,” Regeneron spokesperson Ella Campbell tells Fortune. “We have all of these data ...

Regeneron also hopes for a retinal vein occlusion ... We know the retinal community very well. But we didn’t have all the tools necessary to optimize Eylea HD.” Roche's Vabysmo will rise ...

The center will have exclusive rights to perform all research-related sequencing on samples collected under the collaboration, Regeneron said. Both Regeneron and Truveta will use the data to ...

Regeneron collaborates with Truveta to expand ... up to ten million additional de-identified patient volunteers, all with linked electronic health records (EHRs). This novel resource is designed ...

Regeneron also proffered selected guidance for ... Although that's a bit atypical, all in all it was a solid earnings report for the company. Its portfolio isn't large, but it is a good mix ...

Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. My name is Tawanda, and I will be your operator for today's call. At this time, all participants are ...